What Researchers Did
Researchers reviewed the biology behind altitude sickness in tourists and proposed that hyperbaric oxygen treatment could be a logical way to manage it, based on how low oxygen levels affect the body at high elevation.
What They Found
A narrative review proposes that a clinical hyperbaric chamber built for three atmospheres absolute (3 ATA) could treat altitude sickness using a specific low-pressure profile of 1.25 atmospheres absolute (1.25 ATA), adapted from protocols previously developed for the US military and NASA. The review states that conventional care manages altitude sickness with medication, oxygen, and portable-chamber recompression to an equivalent of 1524 to 2438 meters altitude using devices such as the Gamow Bag, an approach the authors say is not always acceptable for an elderly tourist population. The authors report that their proposed 1.25 ATA profile is intended to virtually eliminate the symptom rebound that conventional treatment often shows when a patient returns directly to the original altitude without recompressing to sea level or greater pressure. The abstract does not include original patient outcome data, sample sizes, or statistical tests supporting this claim.
What This Means for Canadian Patients
For Canadians traveling to high-altitude destinations, this review presents hyperbaric oxygen at 1.25 ATA as a proposed alternative to portable recompression bags, particularly for older travelers who may find a Gamow Bag less practical. Because the abstract describes a theoretical, physiology-based proposal rather than a clinical trial, patients should not assume this approach has been proven more effective than standard acclimatization, medication, and oxygen management for altitude sickness.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As a narrative review proposing a treatment protocol based on pathophysiology rather than a clinical trial, the paper provides no sample size, comparative outcome data, or statistical analysis to confirm the claimed reduction in symptom rebound.